Abcellera Biologics vs Recursion Pharmaceuticals
Abcellera Biologics and Recursion Pharmaceuticals are similar in size: $75.1m and $74.7m of revenue in their latest fiscal years. Abcellera Biologics grew faster (160.6% against 26.9%). Abcellera Biologics kept more of each dollar of sales as profit: a net margin of -194.9% against -863.4%. Abcellera Biologics carries less debt relative to equity (0.0% against 1.6%).
| Latest fiscal year | Abcellera BiologicsABCL, 2025 | Recursion PharmaceuticalsRXRX, 2025 |
|---|---|---|
| Revenue | $75.1m | $74.7m |
| Revenue growth | 160.6% | 26.9% |
| Net income | −$146m | −$645m |
| Operating margin | -289.0% | -867.9% |
| Net margin | -194.9% | -863.4% |
| Return on equity | -14.5% | -59.5% |
| Free cash flow | −$174m | −$378m |
| Cash | $129m | $743m |
| Total debt | $0 | $18.7m |
| Debt to equity | 0.0% | 1.6% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 562 | — |
| Market value | $3.41bn | $2.15bn |
| Price vs our value range | — | — |
| Moat score | 17 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 9 buys, 0 sales | 0 buys, 35 sales |